Track 4D Molecular Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

4D Molecular Therapeutics, Inc. FDMT · Stock Open 4D Molecular Therapeutics, Inc. in new tab

12.23 USD
EPS
-2.63
P/B
1.69
ROE
-43.25
Beta
2.91
Target Price
28.09 USD
Loading chart...
Key Metrics
Earnings dateFeb. 26, 2027
EPS-2.63
Book Value7.38
Price to Book1.69
Debt/Equity9.62
% Insiders2.722%
Growth
Revenue Growth251.07%
Estimates
Forward P/E-3.05
Forward EPS-4.09
Target Mean Price28.09

DCF valuation

Model fair value for 4D Molecular Therapeutics, Inc. (FDMT)
Result
Sign in to run the valuation for FDMT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
11 analysts · consensus None · mean target 28.09 USD (low 18.00, high 37.00) · as of 10 Nov 2026
Low 18.00
Mean 28.09
High 37.00
Price 12.23
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

4D Molecular Therapeutics, Inc. Logo 4D Molecular Therapeutics, Inc. Analysis (FDMT)

United States Health Care Official Website Stock

Is 4D Molecular Therapeutics, Inc. a good investment? 4D Molecular Therapeutics, Inc. (FDMT) is currently trading at 12.23 USD. Market analysts have a consensus price target of 28.09 USD. This suggests a potential upside from current levels.

Earnings Schedule: 4D Molecular Therapeutics, Inc. is expected to release its next earnings report on Feb. 26, 2027. The market consensus estimate for Forward EPS is -4.09.

Investor FAQ

Does 4D Molecular Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is 4D Molecular Therapeutics, Inc.?

4D Molecular Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 26, 2027. The company currently has a trailing EPS of -2.63.

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Exchange Ticker
NMS (United States) FDMT
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion